Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011.
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candidemia is common and associated with high morbidity and mortality; changes in population-based incidence rates have not been reported. METHODS: We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, and Baltimore City/County, Maryland (combined population 5.2 million), during 2008-2011. We calculated candidemia incidence and antifungal drug resistance compared with prior surveillance (Atlanta, 1992-1993; Baltimore, 1998-2000). RESULTS: We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 in Baltimore. Rates were highest among adults aged ≥65 years (Atlanta, 59.1; Baltimore, 72.4) and infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior surveillance, adjusted incidence significantly declined for infants of both black and white race (Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17-.38]; white RR: 0.19 [95% CI, .12-.29]; Baltimore: black RR, 0.38 [95% CI, .22-.64]; white RR: 0.51 [95% CI: .29-.90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluconazole and an echinocandin. CONCLUSIONS: We describe marked shifts in candidemia epidemiology over the past 2 decades. Adults aged ≥65 years replaced infants as the highest incidence group; adjusted incidence has declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, or changes in catheter insertion practices may be contributing to these declines. Further surveillance for antifungal resistance and efforts to determine effective prevention strategies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All-cause in-hospital mortality of candidemia has been reported as high as 36% in the US.27,51,52”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [51]
In the citing paper
“Candidemia is one of the most common health care–associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“In population-based surveillance performed in the metropolitan areas of Atlanta, Georgia, and Baltimore, Maryland, candidemia incidence (primarily among adults) increased 10%–40% from the early 1990s and the late 2000s, which was followed by more recent reports of decreases in these areas (6,28–30).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“This contrasts with data from the early 1990s, when infants had the highest incidence (6), followed by substantial decreases by the late 2000s (26,28).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“The previously reported racial disparity in candidemia persisted in this surveillance period (6), with a 2.3 times higher incidence among blacks than among nonblacks.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198 · cited 1×
“%) met criteria for sepsis [19].”
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
Pronovost, P., Needham, D., Berenholtz, S., Sinopoli, D., Chu, H., Cosgrove, S., Sexton, B., Hyzy, R., Welsh, R., Roth, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061115 · Cited by 4,387 · cited 2×
“…dramatic declines in some central line– associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus , following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida species [20, 24, 34–36].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“shown to decrease risk of disease [21, 25–29].”
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · cited 1×
“Increases in common risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving immunosuppressive therapies [33] may have resulted in increases in the overall pool of patients at high risk for candidemia.”
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“0 %) between centres [2, 14, 18, 31] possibly because of lack of standardized criteria.”
Research works printed but not linked: 2
- 1992, Chest, 10, 1644
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
Cited by
Items 101–200 of 411
Candidemia in children: Epidemiology, prevention and management
Mantadakis, E., Pana, Z. D., & Zaoutis, T. E. (2018) · Mycoses · doi:10.1111/myc.12792 · Cited by 77
Dellière, S., Healey, K., Gits-Muselli, M., Carrara, B., Barbaro, A., Guigue, N., Lecefel, C., Touratier, S., Desnos-Ollivier, M., Perlin, D. S., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02038 · Cited by 75
Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
Forastiero, A., Garcia-Gil, V., Rivero-Menendez, O., Garcia-Rubio, R., Monteiro, M. C., Alastruey-Izquierdo, A., Jordan, R., Agorio, I., & Mellado, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-15 · Cited by 68
“krusei have emerged as important and potentially antifungal (azole)-resistant causes of candidemia (6).”
BackgroundAntifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions
Tragiannidis, A., Γκαμπέτα, Α., Vousvouki, M., Vasileiou, E., & Groll, A. H. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1922667 · Cited by 71
Medically Important Fungi Respond to Azole Drugs: An Update
Zavřel, M., & White, T. C. (2015) · Future Microbiology · doi:10.2217/fmb.15.47 · Cited by 69
Investigating Antifungal Susceptibility in Candida Species With MALDI-TOF MS-Based Assays
Delavy, M., Santos, A. R. D., Heiman, C. M., & Coste, A. T. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00019 · Cited by 66
Antifungal resistance in patients with Candidaemia: a retrospective cohort study
Aldardeer, N. F., Albar, H., Alattas, M., Eldali, A., Qutub, M., Hassanien, A., & Alraddadi, B. M. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-019-4710-z · Cited by 67
Pfaller, M. A., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · The Journal of Antibiotics · doi:10.1038/ja.2015.29 · Cited by 64
A common vesicle proteome drives fungal biofilm development
Zarnowski, R., Sanchez, H., Jaromin, A., Zarnowska, U. J., Nett, J. E., Mitchell, A. P., & Andes, D. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211424119 · Cited by 63
Andrade, J. T., Santos, F. R. D. S., Lima, W. G., de Sousa, C. D. F., Oliveira, L. S. F. M., Ribeiro, R. I. M. D. A., Gomes, A. J. P. S., Araújo, M. G. D. F., Villar, J. A. F. P., & Ferreira, J. M. S. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0048-9 · Cited by 63
Delavy, M., Cerutti, L., Croxatto, A., Prod’hom, G., Sanglard, D., Greub, G., & Coste, A. T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03000 · Cited by 62
Comparative Genomics of Two Sequential Candida glabrata Clinical Isolates
Vale-Silva, L., Beaudoing, E., Tran, V. D. T., & Sanglard, D. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.042887 · Cited by 61
“In a study performed between 2008 and 2011, resistance to fluconazole (cut-off: ≥ 64 μg/ml) or echinocandins (cut-off: ≥4 μg/ml) ranged between 1-2% in bloodstream isolates (Cleveland et al. 2012).”
BackgroundLuzzati, R., Cavinato, S., Giangreco, M., Granà, G., Centonze, S., Deiana, M. L., Biolo, G., & Barbone, F. (2013) · Mycoses · doi:10.1111/myc.12090 · Cited by 52
Ostrosky-Zeichner, L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit140 · Cited by 51
“Case in point: In a recent population-based study of candidemia in the United States, Cleveland et al [7] reported a 7% incidence of fluconazole resistance, 1% incidence of echinocandin resistance, and 0.4% incidence of both echinocandin and fluconazole resistance (8 of 9 isolates were Candida glabrata).”
InfluentialPham, C. D., Bolden, C. B., Kuykendall, R. J., & Lockhart, S. R. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03378-13 · Cited by 51
Self-citationThe Economic Impact of Rapid Candida Species Identification by T2Candida Among High-Risk Patients
Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015) · Future Microbiology · doi:10.2217/fmb.15.29 · Cited by 58
Pankey, G. A., Ashcraft, D. S., Kahn, H. P., & Ismail, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03035-14 · Cited by 58
“glabrata isolates were resistant to both fluconazole and echinocandins (4).”
BackgroundDeciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Soulountsi, V., Schizodimos, T., & Kotoulas, S. (2021) · Infection · doi:10.1007/s15010-021-01640-7 · Cited by 59
Parslow, B. Y., & Thornton, C. R. (2022) · Microorganisms · doi:10.3390/microorganisms10061208 · Cited by 57
“metropolitan site in Georgia in 1992, 2008, 2012 and 2016 [6,44,46].”
BackgroundInfluentialDiagnosis of Invasive Candidiasis: From Gold Standard Methods to Promising Leading-edge Technologies
Pitarch, A., Nombela, C., & Gil, C. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666181025093146 · Cited by 56
“For example, C. glabrata is commonly isolated in Northern in Southern Europe, South America and Asia [17, 19, 21, 24-25].”
BackgroundInfluentialKlotz, U., Schmidt, D., Willinger, B., Steinmann, E., Buer, J., Rath, P., & Steinmann, J. (2016) · Mycoses · doi:10.1111/myc.12472 · Cited by 49
Lewandowska, A., Soutar, C. P., Greenwood, A. I., Nimerovsky, E., Lio, A. M. D., Holler, J. T., Hisao, G. S., Khandelwal, A., Zhang, J., SantaMaria, A. M., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00685-4 · Cited by 55
Vila, T. V. M., Ishida, K., Seabra, S. H., & Rozental, S. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.07.022 · Cited by 54
Al-Baqsami, Z. F., Ahmad, S., & Khan, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-63240-z · Cited by 49
Rybak, J. M., Dickens, C. M., Parker, J. E., Caudle, K. E., Manigaba, K., Whaley, S. G., Nishimoto, A. T., Luna-Tapia, A., Roy, S., Zhang, Q., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00651-17 · Cited by 53
Trends in Epidemiology and Microbiology of Severe Sepsis and Septic Shock in Children
Sehgal, M., Ladd, H. J., & Totapally, B. (2020) · Hospital Pediatrics · doi:10.1542/hpeds.2020-0174 · Cited by 53
Fuller, J., Dingle, T. C., Bull, A., Shokoples, S., Laverdière, M., Baxter, M. R., Adam, H. J., Karlowsky, J. A., Zhanel, G. G., Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD, et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz287 · Cited by 52
Magobo, R. E., Naicker, S. D., Wadula, J., Nchabeleng, M., Coovadia, Y. M., Hoosen, A. A., Lockhart, S. R., Govender, N. P., & the TRAC‐South Africa group (2017) · Mycoses · doi:10.1111/myc.12596 · Cited by 51
Self-citationCandidemia surveillance in Iowa: emergence of echinocandin resistance
Matsumoto, E., Boyken, L., Tendolkar, S., McDanel, J., Castanheira, M., Pfaller, M., & Diekema, D. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.016 · Cited by 50
T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications
Zacharioudakis, I. M., Zervou, F. N., & Mylonakis, E. E. (2018) · Journal of Fungi · doi:10.3390/jof4020045 · Cited by 50
“population-based survey conducted in 2008–2011 [4].”
Sakagami, T., Kawano, T., Yamashita, K., Yamada, E., Fujino, N., Kaeriyama, M., Fukuda, Y., Nomura, N., Mitsuyama, J., Suematsu, H., et al. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.10.007 · Cited by 43
Bustamante, B., Martins, M. A., Bonfietti, L. X., Szeszs, M. W., Jacobs, J. A., García, C., & Melhem, M. D. S. C. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.071167-0 · Cited by 48
“Several studies showed that Candida species distribution and in vitro drug susceptibility vary among countries and even in different regions of a single country (Cleveland et al., 2012; Nishikaku et al., 2010), although most of these studies were conducted in the USA or in Europe.”
ResultPediatric Candidemia Epidemiology and Morbidities: A Nationwide Cohort
Lausch, K. R., Dungu, K. H. S., Callesen, M. T., Schrøder, H. D., Rosthøj, S., Poulsen, A., Østergaard, L. J., Mortensen, K. L., Storgaard, M., Schønheyder, H. C., et al. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002207 · Cited by 47
Dectin-1 multimerization and signaling depends on fungal β-glucan structure and exposure
Anaya, E. U., Amin, A. E., Wester, M. J., Danielson, M. E., Michel, K. S., & Neumann, A. K. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2023.07.021 · Cited by 46
Emergence of resistant Candida glabrata in Germany
Aldejohann, A. M., Herz, M., Martin, R., Walther, G., & Kurzai, O. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab122 · Cited by 41
In vitro activity of 23 tea extractions and epigallocatechin gallate against Candida species
Chen, M., Zhai, L., & Arendrup, M. C. (2015) · Medical Mycology · doi:10.1093/mmy/myu073 · Cited by 45
“glabrata is a serious problem as it could indicate resistance anidulafungin, caspofungin, and micafungin, and if that were the case, only amphotericin B would remain to treat the infection [4–7,33].”
BackgroundPopulation Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
Lakota, E. A., Ong, V. S., Flanagan, S., & Rubino, C. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02603-17 · Cited by 42
“glabrata has not only increased more than 4-fold over the 53 past 20 years [4] but also has been accompanied by increased prevalence of 54”
Patch, M., Weisz, E. E., Cubillos, A. L., Estrada, S. J., & Pfaller, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky046 · Cited by 42
Brunetti, G., Navazio, A. S., Giuliani, A., Giordano, A., Proli, E. M., Antonelli, G., & Raponi, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224678 · Cited by 43
Effects of Propolis on Infectious Diseases of Medical Relevance
Rivera-Yañez, N., Rivera-Yañez, C. R., Pozo‐Molina, G., Méndez-Catalá, C. F., Reyes‐Reali, J., Mendoza‐Ramos, M. I., Méndez‐Cruz, A. R., & Nieto-Yáñez, Ó. (2021) · Biology · doi:10.3390/biology10050428 · Cited by 43
Our 2014 approach to breakthrough invasive fungal infections
Maschmeyer, G., & Patterson, T. F. (2014) · Mycoses · doi:10.1111/myc.12213 · Cited by 43
Friendly fungi: symbiosis with commensal Candida albicans
Shao, T., Haslam, D. B., Bennett, R. J., & Way, S. S. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.07.003 · Cited by 41
Antifungal Activity of Essential Oils Against Candida Species Isolated from Clinical Samples
Córdoba, S. B., Vivot, W., Szusz, W., & Albo, G. N. (2019) · Mycopathologia · doi:10.1007/s11046-019-00364-5 · Cited by 40
Walker, B. S., Powers‐Fletcher, M. V., Schmidt, R. L., & Hanson, K. E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02971-15 · Cited by 40
Florio, W., Tavanti, A., Ghelardi, E., & Lupetti, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02577 · Cited by 41
“albicans remains the most frequently isolated species, other fungal pathogens have been isolated with remarkably increasing frequency; these include Candida glabrata (Cleveland et al., 2012; Pfaller et al., 2014), the emerging pathogen Candida auris (Bao et al.”
BackgroundFuture therapies targeted towards eliminatingCandidabiofilms and associated infections
Bandara, N., Matsubara, V. H., & Samaranayake, L. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1268530 · Cited by 39
Advances in the treatment of invasive neonatal candidiasis
Botero-Calderon, L., Benjamin, D. K., & Cohen‐Wolkowiez, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1031108 · Cited by 38
Personalized machine learning approach to predict candidemia in medical wards
Ripoli, A., Sozio, E., Sbrana, F., Bertolino, G., Pallotto, C., Cardinali, G., Meini, S., Pieralli, F., Azzini, A. M., Concia, E., et al. (2020) · Infection · doi:10.1007/s15010-020-01488-3 · Cited by 38
Invasive Candida Infections in Neonates after Major Surgery: Current Evidence and New Directions
Rose, D. U. D., Santisi, A., Ronchetti, M. P., Martini, L., Serafini, L., Betta, P., Maino, M., Cavigioli, F., Cocchi, I., Pugni, L., et al. (2021) · Pathogens · doi:10.3390/pathogens10030319 · Cited by 38
Scharmann, U., Kirchhoff, L., Chapot, V., Dziobaka, J., Verhasselt, H. L., Stauf, R., Buer, J., Steinmann, J., & Rath, P. (2020) · Mycoses · doi:10.1111/myc.13119 · Cited by 37
Boonstra, J. M., Märtson, A., Sandaradura, I., Kosterink, J. G. W., van der Werf, T. S., Marriott, D. J. E., Zijlstra, J. G., Touw, D. J., & Alffenaar, J. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01554-20 · Cited by 37
Resistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 37
Mencarini, J., Mantengoli, E., Tofani, L., Riccobono, E., Fornaini, R., Bartalesi, F., Corti, G., Farese, A., Pecile, P., Boni, L., et al. (2018) · Infection · doi:10.1007/s15010-018-1139-z · Cited by 36
Viana, R., Dias, Ó., Lagoa, D., Galocha, M., Rocha, I., & Teixeira, M. C. (2020) · Journal of Fungi · doi:10.3390/jof6030171 · Cited by 36
Mete, B., Zerdali, E. Y., Aygün, G., Saltoğlu, N., Balkan, İ. İ., Karaali, R., Kaya, S. Y., Karaismailoglu, B., Kaya, A., Ürkmez, S., et al. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03994-6 · Cited by 36
Decreasing rates of invasive candidiasis in pediatric hospitals across the United States.
Fisher, B. T., Ross, R. K., Localio, A. R., Prasad, P. A., & Zaoutis, T. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit679 · Cited by 35
Development of Lipo-γ-AA Peptides as Potent Antifungal Agents
Zhang, X., Wang, M., Zhu, X., Peng, Y., Fu, T., Hu, C., Cai, J., & Liao, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00595 · Cited by 34
Luzzati, R., Cavinato, S., Deiana, M. L., Rosin, C., Maurel, C., & Borelli, M. (2014) · Aging Clinical and Experimental Research · doi:10.1007/s40520-014-0251-x · Cited by 33
Boric acid destabilizes the hyphal cytoskeleton and inhibits invasive growth of Candida albicans
Pointer, B., Boyer, M. P., & Schmidt, M. (2015) · Yeast · doi:10.1002/yea.3066 · Cited by 33
“Finally, using BA for the treatment of Candida vaginitis would have the added benefit of reducing the use of antifungal drugs and lessen the threat of emerging multidrugresistant strains (Cleveland et al., 2012).”
MethodMagill, S. S., Dumyati, G. K., Ray, S. M., & Fridkin, S. K. (2015) · Emerging infectious diseases · doi:10.3201/eid2109.150508 · Cited by 33
“Analysis of data collected during 2008–2011 in Georgia and Maryland showed marked declines in candidemia in infants, the group that had the highest rates of infection in the 1990s (5).”
BackgroundSelf-citationTetrahydrocarbazoles are a novel class of potent P-type ATPase inhibitors with antifungal activity
Bublitz, M., Kjellerup, L., Cohrt, K. O., Gordon, S. L., Mortensen, A. L., Clausen, J. D., Pallin, T. D., Hansen, J. B., Fuglsang, A. T., Dalby‐Brown, W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0188620 · Cited by 32
“Many of the currently available therapies exhibit poor toxicology profiles (amphotericin B) [2], extensive drug-drug interactions (azoles), and are beginning to suffer from acquired resistance among pathogenic species (azoles and echinocandins) [3,4].”
BackgroundHow much do we know about hemolytic capability of pathogenic Candida species?
Furlaneto, M. C., Góes, H. P., Perini, H. F., dos Santos, R. C., & Furlaneto-Maia, L. (2018) · Folia Microbiologica · doi:10.1007/s12223-018-0584-5 · Cited by 32
Fais, R., Luca, M. D., Rizzato, C., Morici, P., Bottai, D., Tavanti, A., & Lupetti, A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02218 · Cited by 31
“Among these yeasts, although Candida albicans still predominates, infections due to non-albicans species have emerged over the past two decades (van Asbeck et al., 2009; Pfaller et al., 2010; Cleveland et al., 2012).”
BackgroundTiraboschi, I. N., Pozzi, N. C., Farías, L., García, S., & Fernández, N. (2017) · Revista chilena de infectología · doi:10.4067/s0716-10182017000500431 · Cited by 31
Piqueras, A., Ganapathi, L., Carpenter, J. F., Rubio, T. T., Sandora, T. J., Flett, K. B., & Köhler, J. R. (2021) · Journal of Fungi · doi:10.3390/jof7020078 · Cited by 33
Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins
Hori, Y., & Shibuya, K. (2018) · Medical Mycology Journal · doi:10.3314/mmj.18.004 · Cited by 30
Lausch, K. R., Søgaard, M., Rosenvinge, F. S., Johansen, H. K., Boysen, T., Røder, B. L., Mortensen, K. L., Nielsen, L. B., Lemming, L. E., Olesen, B. R. S., et al. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.08.010 · Cited by 30
Biofilm Formation as a Pathogenicity Factor of Medically Important Fungi
Vila, T. V. M., & Rozental, S. (2016) · InTech eBooks · doi:10.5772/62768 · Cited by 30
“albicans [31], especially due to some CNA species that are inherently resistant to antifungals, such as C.”
BackgroundGuo, L., Xiao, M., Cao, B., Qu, F., Zhan, Y., Hu, Y., Wang, X., Liang, G., Gu, H., Qi, J., et al. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0036 · Cited by 30
Pereira, F., & Rammaert, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00230-5 · Cited by 30
Burden of serious fungal infections in Trinidad and Tobago
Denning, D. W., & Gugnani, H. C. (2015) · Mycoses · doi:10.1111/myc.12394 · Cited by 29
Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital
Battistolo, J., Glampedakis, E., Damonti, L., Poissy, J., Grandbastien, B., Kalbermatter, L., Pagani, J., Eggimann, P., Bochud, P., Calandra, T., et al. (2021) · Mycoses · doi:10.1111/myc.13376 · Cited by 29
Milazzo, L., Peri, A. M., Mazzali, C., Grande, R., Cazzani, C., Ricaboni, D., Castelli, A., Raimondi, F., Magni, C. F., Galli, M., et al. (2014) · Mycopathologia · doi:10.1007/s11046-014-9786-9 · Cited by 29
“7 per 10,000 patient/days in 2012, similar to what has been observed in North America [5, 63], in Denmark [6] and in Northern Italy [15].”
BackgroundResultInfluentialMeyahnwi, D., Siraw, B. B., & Reingold, A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07848-8 · Cited by 28
Puig‐Asensio, M., Fernández‐Ruiz, M., Aguado, J. M., Merino, P., Lora, D., Guinea, J., Martín‐Dávila, P., Cuenca‐Estrella, M., & Almirante, B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-16 · Cited by 28
“glabrata isolates would be covered in settings with low rates of resistance to fluconazole, such as Spain, some areas of the United States, Northern Europe, and South America (8, 18, 33, 34).”
BackgroundThe burden of fungal disease in Denmark
Mortensen, K. L., Denning, D. W., & Arendrup, M. C. (2015) · Mycoses · doi:10.1111/myc.12383 · Cited by 27
Endogenous Candida endophthalmitis: Who is really at risk?
Seidelman, J., Fleece, M., Bloom, A., Lydon, E., Yang, W., Arnold, C., Weber, D. J., & Okeke, N. L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2020.12.032 · Cited by 26
Vargas-Espíndola, L. A., Cuervo, S. I., Enciso-Olivera, J. L., Gómez-Rincón, J. C., Cetina, L. P. J., Sánchez, R., García-Guzmán, K., López-Mora, M. J., Álvarez, C., Cortés, J. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9040400 · Cited by 26
Mendoza-Juache, A., Aranda‐Romo, S., Bermeo‐Escalona, J. R., Gómez-Hernández, A., Pozos‐Guillén, A., & Sánchez-Vargas, L. O. (2017) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.11.008 · Cited by 26
Pushing the Limits of MALDI-TOF Mass Spectrometry: Beyond Fungal Species Identification
Rizzato, C., Lombardi, L., Zoppo, M., Lupetti, A., & Tavanti, A. (2015) · Journal of Fungi · doi:10.3390/jof1030367 · Cited by 25
“Among the most significant emerging pathogens are yeast such as Candida glabrata [3,4], Trichosporon spp.”
BackgroundAigner, M., Erbeznik, T., Gschwentner, M., & Lass‐Flörl, C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00512-17 · Cited by 25
Asadzadeh, M., Alanazi, A. F., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223920 · Cited by 25
Candida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells
Herwald, S. E., & Kumamoto, C. A. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0178-x · Cited by 25
Pongrácz, J., Juhász, E., Iván, M., & Kristóf, K. (2015) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.62.2015.3.9 · Cited by 24
“0 / 100 000 inhabitants) [2–6].”
Sharifi, M., Badiee, P., Abastabar, M., Morovati, H., Haghani, I., Noorbakhsh, M., & Mohammadi, R. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1152552 · Cited by 23
Biomimetic Antifungal Materials: Countering the Challenge of Multidrug-Resistant Fungi
Khalifa, H. O., Oreiby, A. F., Abdelhamid, M. A. A., Ki, M., & Pack, S. P. (2024) · Biomimetics · doi:10.3390/biomimetics9070425 · Cited by 24
“These drugs are the preferred treatment for various types of candidiasis, with about 60% of candidaemia patients receiving echinocandin therapy [33].”
BackgroundEmerging Infections Program as Surveillance for Antimicrobial Drug Resistance
Fridkin, S. K., Cleveland, A. A., See, I., & Lynfield, R. (2015) · Emerging infectious diseases · doi:10.3201/eid2109.150512 · Cited by 23
“Data collected from Georgia and Maryland EIP sites during 2008–2011 showed that, during a period of general adopton of fluconazole prophylaxis in infants of extremely low birthweight to prevent neonatal candidemia, rates of candidemia in infants markedly declined (11) and levels of fluconazole resistance among Candida…”
BackgroundSelf-citationReal-Time Approach to Flow Cell Imaging of Candida albicans Biofilm Development
McCall, A. D., & Edgerton, M. (2017) · Journal of Fungi · doi:10.3390/jof3010013 · Cited by 23
“Despite improvements in treatment modalities, mortality rates for these infections remain relatively high, in part due to drug resistance [2].”
BackgroundAlobaid, K., & Khan, Z. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.12.001 · Cited by 23
Pitarch, A., Nombela, C., & Gil, C. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.10.022 · Cited by 23
Fisher, B. T., Vendetti, N., Bryan, M. W., Prasad, P. A., Localio, A. R., Damianos, A., Coffin, S. E., Bell, L. M., Walsh, T. J., Gross, R., et al. (2015) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piv048 · Cited by 23
“Recent data suggest a decline in the rate of candidemia among pediatric patients [2–4].”
BackgroundVaňková, E., Kašparová, P., Dulíčková, N., & Čeřovský, V. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa020 · Cited by 22
Martín-Gutiérrez, G., Peñalva, G., de Pipaón, M. R.-P., Aguilar, M., Gil-Navarro, M. V., Perez-Blanco, J.-L., Pérez-Moreno, M. A., Amaya‐Villar, R., Ferrándiz‐Millón, C., Gascón, M. L., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.01.002 · Cited by 22
INVASIVE FUNGAL INFECTION IN CHILDREN WITH ACUTE LEUKEMIA AND SEVERE APLASTIC ANEMIA
Supatharawanich, S., Narkbunnam, N., Vathana, N., Takpradit, C., Phuakpet, K., Pongtanakul, B., Tongsai, S., Sinlapamongkolkul, P., Ngamskulrungroj, P., Phongsamart, W., et al. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.039 · Cited by 22
The Overlooked Immune State in Candidemia: A Risk Factor for Mortality
Ortega‐Loubon, C., Cano-Hernández, B., Poves‐Álvarez, R., Muñoz-Moreno, M. F., Román-García, P., Balbás-Alvarez, S., de la Varga-Martínez, O., Gómez‐Sánchez, E., Gómez‐Pesquera, E., Lorenzo‐López, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101512 · Cited by 21
Antimycotic Drugs and their Mechanisms of Resistance to Candida Species
Dahiya, S., Sharma, N., Punia, A., Choudhary, P., Gulia, P., Parmar, V. S., & Chhillar, A. K. (2021) · Current Drug Targets · doi:10.2174/1389450122666210719124143 · Cited by 22
Suzuki, H., Perencevich, E. N., Diekema, D. J., Livorsi, D. J., Nair, R., Kralovic, S. M., Roselle, G. A., & Goto, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab105 · Cited by 20
Vasileiou, E., Paisiou, A., Tsipou, C., Pourtsidis, A. G., Galani, V., Katzilakis, N., Antoniadi, K., Papakonstantinou, Ε., Ioannidou, E., Stiakaki, E., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040276 · Cited by 20
From synthetic DNA to PCR product: detection of fungal infections using SERS
Mabbott, S. B., Thompson, D., Sirimuthu, N. M. S., McNay, G., Faulds, K., & Graham, D. (2015) · Faraday Discussions · doi:10.1039/c5fd00167f · Cited by 20
Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery
Li, C., Lev, S., Saiardi, A., Desmarini, D., Sorrell, T. C., & Djordjevic, J. T. (2016) · Journal of Fungi · doi:10.3390/jof2030024 · Cited by 20
Metadata
- Authors
- Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M.
- Affiliations
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-14
- Volume
- 55
- Issue
- 10
- Pages
- 1352-1361
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2157512355
- Cited by
- 366
- References
- 138
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 17 · 2023: 16 · 2022: 23 · 2021: 32 · 2020: 35 · 2019: 21 · 2018: 42 · 2017: 35 · 2016: 28 · 2015: 44 · 2014: 33 · 2013: 19 · 2012: 2
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, candidemia incidence, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, multidrug resistance, infants, older adults, epidemiological trends, antifungal prophylaxis, infection control, catheter-related infection, Atlanta, Baltimore
- MeSH terms
- Adolescent, Adult, Aged, Antifungal Agents, Candida, Child, Child, Preschool, Female, Georgia, Humans, Infant, Male, Middle Aged, Population Surveillance, Prospective Studies, Baltimore, Incidence, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.